Kadmos Capital Research
Investment Thesis
Kadmos Capital is a London-based venture capital firm founded in 2021 by Remy Kesrouani and John Gebeily, investing at the intersection of science, technology and ambition. The firm's public positioning ("We are all invested") centers on backing high-impact technologies that address humanity's biggest challenges: the future of the species, a prosperous and habitable planet, and unrealised human potential. Kadmos organizes its own portfolio under three thematic banners it publishes directly on its site: #AI & DATA, #TechBio, and #Sustainability. In practice this means deep-tech and impactful-tech bets spanning generative AI infrastructure, AI-driven drug discovery and diagnostics, and climate/sustainability hardware and software. The firm is registered with the UK FCA under an EuVECA license (FRN 954103), reflecting its European early-stage venture capital fund structure.
Stage Focus
Kadmos invests at the earliest stages of company formation, primarily Pre-Seed, Seed, and selectively Series A. Portfolio evidence shows the firm co-leading or participating in first institutional rounds (Big Picture Bio pre-seed, XONAI's early funding) as well as following into seed rounds alongside other early-stage specialists (InTouchNow AI's seed round led by Ada Ventures, GlycanAge's seed round led by LAUNCHub Ventures).
Check Size
No check-size range is published on the firm's website or found in third-party sources with sufficient confidence to report a figure; this remains an open gap in the profile.
Lead Tendency
Kadmos shows a mixed lead/follow pattern. It has led or co-led rounds directly (Big Picture Bio's pre-seed co-led with Exceptional Ventures; XONAI's funding round explicitly "led by Kadmos Capital"), and it has also taken participating positions in rounds led by other funds (InTouchNow AI's seed led by Ada Ventures with Kadmos and Exceptional Ventures participating; GlycanAge's seed led by LAUNCHub Ventures with Kadmos co-investing).
Recent Activity
Kadmos has been active through 2026, with a new pre-seed investment in Big Picture Bio (AI-designed cancer combination therapies, September 2026) and a seed investment in InTouchNow AI (AI voice agents for NHS GP practices, September 2026). Third-party aggregators (Dealroom) report assets under management of approximately $52.6M and roughly 13+ tracked portfolio positions, consistent with the firm's own published news feed, which documents ongoing milestones across its book — grant wins, follow-on rounds, and strategic partnerships — through early 2026.
Portfolio Highlights
Kadmos's named portfolio spans three thematic clusters:
- AI & Data: Stability AI (generative media, notable for its EA and Universal Music Group partnerships and a reported $1B seed valuation), Pathway (post-transformer "BDH" AI architecture), XONAI (accelerated computing for data infrastructure), InTouchNow AI (AI voice agents for NHS primary care).
- TechBio: Pangea Bio (neuroprotective drug discovery, Michael J. Fox Foundation-funded Parkinson's research), Big Picture Bio (AI-designed cancer combination therapies), Antiverse (generative AI antibody design), Plurify (programmable RNA platform for cell and gene therapy manufacturing), GlycanAge (glycan-based biological age testing), iFAST Diagnostics (rapid antimicrobial susceptibility testing), Chemastery (AI-driven lab automation for chemistry R&D), Jua (AI Earth Intelligence Platform for energy and weather).
- Sustainability: Kelpi (seaweed-derived bioplastic replacing single-use plastic packaging), DEScycle (critical metals recovery from e-waste), Zora Ecosystems (geospatial data platform for natural capital and forest regeneration).
Team
- Remy Kesrouani — Managing Partner and co-founder. Previously a Partner at Calibrate Management; educated at Bayes Business School, London.
- John Gebeily — General Partner and co-founder. Trained as a biologist and licensed pharmacist; prior healthcare-sector investment and Chief Investment Officer experience; studied at ESCP Business School, Aston University, and Lebanese American University.
- Graham York — Technology Partner. Active on the boards of the firm's deep-tech and infrastructure investments (e.g., XONAI).
Decision Process
With three named partners and a small, hands-on team, Kadmos operates as a partnership-style decision process rather than a large investment committee. Partners are directly quoted backing individual deals (e.g., Remy Kesrouani on Big Picture Bio, Graham York on XONAI), suggesting deal sponsorship by individual partners with partnership-level sign-off.
Founder Preferences
Kadmos gravitates toward technical and scientific founders tackling hard, high-impact problems — AI researchers building novel architectures, biologists and clinicians building diagnostic or therapeutic platforms, and deep-tech engineers building infrastructure. Remy Kesrouani's comment on backing Big Picture Bio's founders ("I had the privilege of working closely with Kerstin and Mark at the very beginning") signals a preference for founders the firm has tracked and built conviction in over time, consistent with a thesis-driven, relationship-first sourcing style rather than pure inbound deal flow.
Geographic Focus
Kadmos is headquartered in London (Fora United House, 9 Pembridge Road, Notting Hill, London, W11 3JY) and invests primarily in UK and European deep-tech companies, with selective exposure beyond Europe (e.g., Jua is Zurich-based; Stability AI is a global company with UK/US ties).